IV Vancomycin

DRUG4 trials

Sponsors

Melinta Therapeutics, Inc., Washington University School of Medicine, CAMC Health System

Conditions

AbscessCellulitisInfectionObesitySepsisSurgical Site InfectionSystemic InflammationWound Infection

Phase 1

Dose Escalation Trial of Intrasite Vancomycin Pharmacokinetics

TerminatedNCT01764750

Washington University School of MedicineSurgical Site Infection

Start: 2013-01-31End: 2013-12-31Updated: 2018-05-11

Phase 3

Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection

CompletedNCT01252732

Melinta Therapeutics, Inc.Abscess, Cellulitis, Systemic Inflammation +1

Start: 2010-12-31End: 2013-06-30Updated: 2021-05-05

Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)

CompletedNCT01252719

Melinta Therapeutics, Inc.Abscess, Cellulitis, Systemic Inflammation +1

Start: 2010-12-31End: 2012-11-30Updated: 2022-08-01

Unknown Phase

Study of Obese Patients Comparing Two Vancomycin Loading Dose Regimens

CAMC Health SystemInfection, Obesity, Sepsis

Start: 2016-08-01End: 2021-01-22Target: 128Updated: 2020-02-05

Related Papers

Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies

Antimicrobial Agents and Chemotherapy2018-01-1823 citations

Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting

Infectious Diseases and Therapy2016-07-0117 citations

Single-Dose Oritavancin Versus 7–10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study

Clinical Infectious Diseases2014-10-06215 citations

Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections

New England Journal of Medicine2014-06-04298 citations